Datavault AI Forms DelivMeds AI Venture Through Wellgistics Partnership, Aiming to Transform Healthcare Delivery

Datavault AI Inc. (NASDAQ: DVLT) announced a binding term sheet with Wellgistics Health Inc. (NASDAQ: WGRX) to establish DelivMeds AI, a healthcare platform that integrates AI-driven pharmacy optimization, blockchain-enabled smart contracts, biometric verification, and direct-to-consumer healthcare delivery. The venture involves three concurrent transactions: an expanded PharmacyChain™ license, acquisition of QOLPOM intellectual property, and a controlling stake in Tollo Health. The combined transactions carry an expected approximate asset value of $4 billion, subject to an independent fairness opinion, and are intended to support a national rollout of data-driven healthcare delivery and patient engagement solutions.

This strategic move positions Datavault AI at the intersection of artificial intelligence and healthcare, leveraging its expertise in data monetization and Web 3.0 technologies. The DelivMeds AI platform aims to streamline pharmacy operations, enhance patient verification through biometrics, and enable secure smart contracts for healthcare transactions. By combining AI analytics with blockchain, the platform could reduce inefficiencies in prescription fulfillment, improve medication adherence, and offer personalized health insights.

The partnership with Wellgistics Health, a company focused on pharmacy benefit management and direct-to-consumer health services, provides a ready channel for deployment. The acquisition of QOLPOM intellectual property adds technology for quality-of-life measurement, while Tollo Health brings capabilities in patient engagement and outcomes tracking. Together, these assets form a comprehensive ecosystem that could address fragmented healthcare delivery systems.

Datavault AI’s technology suite, which includes acoustic sciences and data science divisions, will be central to the venture. The company’s cloud-based platform offers high-performance computing for digital twins, secure data anchoring, and AI-driven automation. The DelivMeds AI initiative represents a significant expansion beyond Datavault’s traditional focus on data valuation and monetization into healthcare applications.

The $4 billion valuation underscores the scale of ambition, though it is subject to an independent fairness opinion, indicating that final terms may adjust. The national rollout plan suggests rapid scaling, potentially impacting millions of patients through improved pharmacy services and direct-to-consumer health products.

For Datavault AI, this venture diversifies its revenue streams and applies its AI and blockchain capabilities to a high-growth sector. Healthcare spending in the U.S. continues to rise, and technology-driven solutions that reduce costs and improve outcomes are in high demand. If successful, DelivMeds AI could set a precedent for similar partnerships, blending fintech, biotech, and AI in healthcare.